融券方面，盈康生命9月30日融券偿还1.68万股，融券卖出200.00股，按当日收盘价计算，卖出金额 2284.00元；融券余量2.60万股，融券余额29.69万元，低于近一年50%分位水平，处于较低位。 9月30日，盈康生命涨1.78%，成交额1.24亿元。两融数据显示，当日盈康生命获融资买入额1362.79万 元，融资偿还2728.17万元，融资净买入-1365.37万元。截至9月30日，盈康生命融资融券余额合计2.69 亿元。 融资方面，盈康生命当日融资买入1362.79万元。当前融资余额2.69亿元，占流通市值的3.67%，融资余 额超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 截至9月19日，盈康生命股东户数2.05万，较上期减少16.28%；人均流通股31286股，较上期增加 19.45%。2025年1月-6月，盈康生命实现营业收入8.43亿元，同比增长2.40%；归母净利润6182.72万元， 同比增长12.82%。 分红方面，盈康生命A股上市后累计派现2948.00万元。近三年，累计派现0.00元。 资料显示，盈康生命科技股份有限公司位于山东省青岛市崂山区海尔路1号盈康一生大厦17 ...

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a positive stock performance with a year-to-date increase of 24.46% and a recent price of 11.45 CNY per share, despite some fluctuations in trading volume and net capital outflow [1] - As of September 19, the number of shareholders for Yingkang Life decreased by 16.28% to 20,500, while the average circulating shares per person increased by 19.45% to 31,286 shares [2] - The company reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million CNY, which is a 12.82% increase year-on-year [2] Group 2 - Yingkang Life specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation, with a revenue composition of 77.47% from medical services and 22.53% from medical devices and consumables [2] - The company has cumulatively distributed 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [1] - The company primarily operates in the medical device and medical services sectors, focusing on the research, production, and sales of advanced medical equipment such as the Maxip radiation therapy equipment and Gamma Knife [1] - The revenue composition of the company is 77.47% from medical services, with 22.53% from equipment and consumables, and another 22.53% from medical devices [1] Stock Performance - On September 23, Yingkang Life's stock fell by 5%, trading at 11.02 CNY per share, with a total transaction volume of 92.35 million CNY and a turnover rate of 1.27%, resulting in a total market capitalization of 8.259 billion CNY [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Galaxy Fund has a significant position in Yingkang Life [2] - The Galaxy Kangle Stock A fund (519673) increased its holdings by 184,000 shares in the second quarter, bringing its total to 930,900 shares, which accounts for 5.06% of the fund's net value, making it the sixth-largest holding [2] - The fund has experienced a floating loss of approximately 539,900 CNY as of the latest report [2] Fund Manager Information - The fund manager of Galaxy Kangle Stock A is Fang Wei, who has been in the position for 4 years and 138 days [3] - The total asset size of the fund is 671 million CNY, with the best and worst fund returns during the manager's tenure being -4.55% and -18.43%, respectively [3]

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a significant increase in stock price and trading activity, indicating positive market sentiment despite recent fluctuations [1][2] - As of September 19, Yingkang Life's stock price rose by 2.08% to 11.76 CNY per share, with a total market capitalization of 8.814 billion CNY [1] - The company has experienced a year-to-date stock price increase of 27.83%, with a recent decline of 8.55% over the last five trading days [1] Group 2 - Yingkang Life, established on August 6, 1998, and listed on December 9, 2010, is based in Qingdao, Shandong Province, and specializes in medical devices and services [2] - The company's main business segments include the development, production, and sales of medical equipment, particularly focusing on cancer treatment technologies [2] - As of September 10, the number of shareholders increased by 22.06% to 24,500, while the average circulating shares per person decreased by 18.07% to 26,191 shares [2] Group 3 - Yingkang Life reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit of 61.83 million CNY, up 12.82% year-on-year [2] - The company has distributed a total of 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]